Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].

Bulletin du cancer - 1 Dec 2009

Blons H, Laurent-Puig P

Abstract excerpt

Targeted therapy against the EGF receptor was shown to be effective in a subgroup of patients with KRAS wild-type colorectal cancer. Therefore, cetuximab (Erbitux) or panitumumab (Vectibix) obtained the authorization by the EMEA restricted to patients with KRAS wild-type tumours. KRAS mutational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to France

Share to Genes, ras

Share to Panitumumab

Share to Quality Control

Source

Identifiers

PMID: 20034870
DOI: 10.1684/bdc.2009.0996

Genes

KRAS
EGF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20034870-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].PMID 20034870Read ↗

[Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].Semantic proximity Read ↗

[Validation study of KRAS mutation in colorectal cancer].Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].Semantic proximity Read ↗

[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].Semantic proximity Read ↗

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.Semantic proximity Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.Semantic proximity Read ↗

[Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.